1. bookVolumen 70 (2020): Edición 2 (June 2020)
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

Effects of new generation triptans – frovatriptan and almotriptan – on hemodynamic parameters in intact male and female rats

Publicado en línea: 16 Jan 2020
Volumen & Edición: Volumen 70 (2020) - Edición 2 (June 2020)
Páginas: 239 - 247
Aceptado: 13 May 2019
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. G. Mancia, E. A. Rosei, E. Ambrosioni, F. Avino, A. Carolei, M. Daccò, G. Di Giacomo, C. Ferri, I. Grazioli, G. Melzi, G. Nappi, L. Pinessi, G. Sandrini, B. Trimarco and G. Zanchin, MIRACLES Study Group. Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study), J. Hypertens.29 (2011) 309–318; https://doi.org/10.1097/HJH.0b013e328341040410.1097/HJH.0b013e3283410404Search in Google Scholar

2. E. P. Widmeier, H. Raff and K. T. Strang, Vander’s Human Physiology: The Mechanisms of Body Function, 13th ed., McGraw-Hill, New York 2014 pp. 408–413.Search in Google Scholar

3. S. W. Watts, S. F. Morrison, R. P. Davis and S. M. Barman, Serotonin and blood pressure regulation, Pharmacol. Rev.64 (2012) 359–388; https://doi.org/10.1124/pr.111.00469710.1124/pr.111.004697Search in Google Scholar

4. F. Côté, C. Fligny, Y. Fromes, J. Mallet and G. Vodjdani, Recent advances in understanding serotonin regulation of cardiovascular function, Trends Mol. Med.10 (2004) 232–238; https://doi.org/10.1016/j.molmed.2004.03.00710.1016/j.molmed.2004.03.007Search in Google Scholar

5. D. W. Dodick and V. Papademetriou, Cardiovascular safety of triptans, Cephalalgia24 (2004) 513–514; https://journals.sagepub.com/doi/10.1111/j.1468-2982.2003.00714.x10.1111/j.1468-2982.2003.00714.xSearch in Google Scholar

6. V. Tullo, G. Bussone, S. Omboni, P. Barbanti, P. Cortelli, M. Curone, C. Peccarisi, C. Benedetto, D. Pezzola, D. Zava and G. Allais, Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies, Neurol. Sci.34 (2013) 87–91; https://doi.org/10.1007/s10072-013-1367-z10.1007/s10072-013-1367-zSearch in Google Scholar

7. S. Watts and R. Davis, 5-Hydroxtryptamine receptors in systemic hypertension: an arterial focus, Cardiovasc. Ther.29 (2011) 54–67; https://doi.org/10.1111/j.1755-5922.2010.00173.x10.1111/j.1755-5922.2010.00173.xSearch in Google Scholar

8. M. Reboredo, H. C. Y. Chang, R. Barbero, C. M. Rodríguez-Ortigosa, F. Pérez-Vizcaíno, A. Morán, M. García, J. M. Banales, N. Carreño, F. Alegre, I. Herrero, J. Quiroga, J. Prieto and B. Sangro, Zolmitriptan: a novel portal hypertensive agent which synergizes with propranolol in lowering portal pressure, PLoS ONE8 (2013) e52683 (9 pages); https://doi.org/10.1371/journal.pone.005268310.1371/journal.pone.0052683Search in Google Scholar

9. T. Gori, J. S. Floras and J. D. Parker, Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans, J. Am. Coll. Cardiol.40 (2002) 2000–2005; https://doi.org/10.1016/S0735-1097(02)02532-910.1016/S0735-1097(02)02532-9Search in Google Scholar

10. A. Negro, L. Lionetto, B. Casolla, N. Lala, M. Simmaco and P. Martelletti, Pharmacokinetic evaluation of frovatriptan, Expert Opin. Drug Metab. Toxicol.7 (2011) 1449–1458; https://doi.org/10.1517/17425255.2011.62226510.1517/17425255.2011.62226521929465Search in Google Scholar

11. A. Matthys, G. Haegeman, K. Van Craenenbroeck and P. Vanhoenacker, Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives, Mol. Neurobiol.43 (2011) 228–253; https://doi.org/10.1007/s12035-011-8175-310.1007/s12035-011-8175-321424680Search in Google Scholar

12. D. Guseva, A. Wirth and E. Ponimaskin, Cellular mechanisms of the 5-HT7 receptor-mediated signaling, Front. Behav. Neurosci.8 (2014) Article ID 306 (8 pages); https://doi.org/10.3389/fnbeh.2014.0030610.3389/fnbeh.2014.00306Search in Google Scholar

13. M. B. Comer, Pharmacology of the selective 5-HT1B/1D agonist frovatriptan, Headache42 (2002) 47–53; https://doi.org/10.1046/j.1526-4610.42.s2.2.x10.1046/j.1526-4610.42.s2.2.xSearch in Google Scholar

14. J. Gras, J. Llenas, J. M. Jansat, J. Jáuregui, X. Cabarrocas and J. M. Palacios, Almotriptan, a new anti-migraine agent: a review, CNS Drug Rev.8 (2002) 217–234; https://doi.org/10.1111/j.1527-3458.2002.tb00226.x10.1111/j.1527-3458.2002.tb00226.xSearch in Google Scholar

15. A. G. Ramage, Central cardiovascular regulation and 5-hydroxytryptamine receptors, Brain Res.Bull.56 (2001) 425–439; https://doi.org/10.1016/S0361-9230(01)00612-810.1016/S0361-9230(01)00612-8Search in Google Scholar

16. M. Van den Buuse and N. Wegener, Involvement of serotonin1A receptors in cardiovascular responses to stress: a radio-telemetry study in four rat strains, Eur. J. Pharmacol.507 (2005) 187–198; https://doi.org/10.1016/j.ejphar.2004.11.04810.1016/j.ejphar.2004.11.04815659309Search in Google Scholar

17. F. Pagniez, J. P. Valentin, S. Vieu, F. C. Colpaert and G. W. John, Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat, Br. J. Pharmacol.123 (1998) 205–214; https://doi.org/10.1038/sj.bjp.070159310.1038/sj.bjp.070159315651559489607Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo